Abiopharma

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Dentsply Sirona Reports Third Quarter 2025 Results

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

Vericel Reports Third Quarter 2025 Financial Results